Gary R Matzke1, Leticia R Moczygemba2, Karen J Williams3, Michael J Czar4, William T Lee5. 1. Department of Pharmacotherapy and Outcome Sciences, Virginia Commonwealth University School of Pharmacy, Richmond, VA. gmatzke2440@gmail.com. 2. Health Outcomes and Pharmacy Practice Division, University of Texas at Austin College of Pharmacy, Austin, TX. 3. Medication Assistance Program, Carilion Clinic, Roanoke, VA. 4. Department of Pharmacy, Carilion New River Valley Medical Center, Christiansburg, VA. 5. Carilion Clinic, Roanoke, VA.
Abstract
PURPOSE: The impact of a pharmacist-physician collaborative care model on patient outcomes and health services utilization is described. METHODS: Six hospitals from the Carilion Clinic health system in southwest Virginia, along with 22 patient-centered medical home (PCMH) practices affiliated with Carilion Clinic, participated in this project. Eligibility criteria included documented diagnosis of 2 or more of the 7 targeted chronic conditions (congestive heart failure, hypertension, hyperlipidemia, diabetes mellitus, asthma, chronic obstructive pulmonary disease, and depression), prescriptions for 4 or more medications, and having a primary care physician in the Carilion Clinic health system. A total of 2,480 evaluable patients were included in both the collaborative care group and the usual care group. The primary clinical outcomes measured were the absolute change in values associated with diabetes mellitus, hypertension, and hyperlipidemia management from baseline within and between the collaborative care and usual care groups. RESULTS: Significant improvements (p < 0.01) in glycosylated hemoglobin, blood pressure, low-density-lipoprotein cholesterol, and total cholesterol were observed in the collaborative care group compared with the usual care group. Hospitalizations declined significantly in the collaborative care group (23.4%), yielding an estimated cost savings of $2,619 per patient. The return on investment (net savings divided by program cost) was 504%. CONCLUSION: Inclusion of clinical pharmacists in this physician-pharmacist collaborative care-based PCMH model was associated with significant improvements in patients' medication-related clinical health outcomes and a reduction in hospitalizations.
PURPOSE: The impact of a pharmacist-physician collaborative care model on patient outcomes and health services utilization is described. METHODS: Six hospitals from the Carilion Clinic health system in southwest Virginia, along with 22 patient-centered medical home (PCMH) practices affiliated with Carilion Clinic, participated in this project. Eligibility criteria included documented diagnosis of 2 or more of the 7 targeted chronic conditions (congestive heart failure, hypertension, hyperlipidemia, diabetes mellitus, asthma, chronic obstructive pulmonary disease, and depression), prescriptions for 4 or more medications, and having a primary care physician in the Carilion Clinic health system. A total of 2,480 evaluable patients were included in both the collaborative care group and the usual care group. The primary clinical outcomes measured were the absolute change in values associated with diabetes mellitus, hypertension, and hyperlipidemia management from baseline within and between the collaborative care and usual care groups. RESULTS: Significant improvements (p < 0.01) in glycosylated hemoglobin, blood pressure, low-density-lipoprotein cholesterol, and total cholesterol were observed in the collaborative care group compared with the usual care group. Hospitalizations declined significantly in the collaborative care group (23.4%), yielding an estimated cost savings of $2,619 per patient. The return on investment (net savings divided by program cost) was 504%. CONCLUSION: Inclusion of clinical pharmacists in this physician-pharmacist collaborative care-based PCMH model was associated with significant improvements in patients' medication-related clinical health outcomes and a reduction in hospitalizations.
Authors: Gina D Moore; Anne L Burns; Hannah Fish; Nidhi Gandhi; Clark Kebodeaux; Lisa M Meny; Anne Policastri; Kevin B Sneed; Andy Traynor; Alexis Vosooney; Lynette R Bradley-Baker Journal: Am J Pharm Educ Date: 2020-10 Impact factor: 2.047
Authors: Linda Awdishu; Renu F Singh; Ila Saunders; Felix K Yam; Jan D Hirsch; Sarah Lorentz; Rabia S Atayee; Joseph D Ma; Shirley M Tsunoda; Jennifer Namba; Christina L Mnatzaganian; Nathan A Painter; Jonathan H Watanabe; Kelly C Lee; Charles D Daniels; Candis M Morello Journal: Pharmacy (Basel) Date: 2019-10-11
Authors: Jennifer Valeska Elli Brown; Nick Walton; Nicholas Meader; Adam Todd; Lisa Ad Webster; Rachel Steele; Stephanie J Sampson; Rachel Churchill; Dean McMillan; Simon Gilbody; David Ekers Journal: Cochrane Database Syst Rev Date: 2019-12-23
Authors: Sarah N Musy; Olga Endrich; Alexander B Leichtle; Peter Griffiths; Christos T Nakas; Michael Simon Journal: J Med Internet Res Date: 2020-04-02 Impact factor: 5.428